Skip to content

Depression: all studies

Page 249 of 1,034: studies 2,481 to 2,490 of 10,336, newest first. Back to the depression overview

Research

Could ketamine be the answer to treating treatment-resistant major depressive disorder?

General Psychiatry August 1, 2020 Abdullah Ramadan, I. Mansour 16 citations

Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by the Food and Drug Administration in 2019, is a potential treatment option for those recalcitrant...

Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression.

Translational Psychiatry July 30, 2020 Ashish K Sahib, Joana Ra Loureiro, Megha M Vasavada et al. 37 citations

Subanesthetic ketamine is found to induce fast-acting and pronounced antidepressant effects, even in treatment resistant depression (TRD). However, it remains unclear how ketamine modulates neural function at the brain systems-level to regulate emotion and behavior. Here, we examined treatment-related changes in the inhibitory control network after single and repeated ketamine therapy in TRD....

A randomised trial comparing a brief online delivery of mindfulness-plus-values versus values only for symptoms of depression: Does baseline severity matter?

Journal of Affective Disorders July 21, 2020 Jessica Kingston, L. Becker, J. Woeginger et al.

BACKGROUND Acceptance/mindfulness-based interventions often focus on (a) developing dispositional mindfulness and (b) pursuing personally meaningful and valued activities. Acceptance/mindfulness-based interventions can reduce depression, but little is known about the combined effects of components or the influence of baseline variables on outcomes. This study tested whether practicing a brief...

Prolonged Remission of Major Depressive Disorder After Single Nitrous Oxide Inhalation Treatment

Frontiers in Psychiatry July 17, 2020 Peter Nagele, Frank Brown, Victoria Bass et al.

Nitrous oxide (N2O, laughing gas) has shown early promise as a rapidly acting treatment for treatmentresistant major depression (1–3). Antidepressant effects of nitrous oxide in these studies started within 2 h and lasted up to 1 week. Due to the study design, however, it was impossible to determine whether antidepressant efficacy lasted beyond 1 week after nitrous oxide administration. There...

5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology

arXiv Preprint Archive July 16, 2020 Camile Bahi preprint

As the world's first primary morbidity factor, depression has a considerable impact on both an individual as well as a societal level. despite their discovery several decades ago, classical antidepressants have been shown to provide limited benefits against this condition. However, substances such as ketamine and psychedelics have recently shown promising results and even received the grade of...

Full text (opens in new tab) Q-bio.qm Q-bio.nc Psychopharmacology Mental-health

Effects of mindfulness meditation interventions on depression in older adults: A meta-analysis

Aging & Mental Health July 15, 2020 Chuntana Reangsing, Tanapa Rittiwong, J. Schneider

Abstract Objective We examined the effects of MMIs on depression in older adults and explored the moderating effects of participant, methods, and intervention characteristics. Methods We systematically searched 15 databases through June 2019 without date restrictions using the following search terms: (mindful* OR meditat*) AND depress* AND (older adult* OR elder OR aging OR senior OR...

Safety of Repeated Administration of Parenteral Ketamine for Depression

Pharmaceuticals July 13, 2020 David Feifel, David Dadiomov, Kelly C. Lee

The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to...

Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-κB/IDO-1 signaling.

Neurochemistry International July 8, 2020 A. Camargo, A. P. Dalmagro, Julia M. Rosa et al.

Augmentative treatment is considered the best second-option when a first-choice drug has partial limitations, particularly by allowing antidepressant dose reduction. Considering that ketamine has significant knock-on effects, this study investigated the effects of single coadministration with subthreshold doses of ketamine plus guanosine in a corticosterone (CORT)-induced animal model of...